Table 1.
Clinicopathological characteristics associated with expressions of lncRNAs which showed a relation with survival.
| Characteristics | All patients (n = 108) | LncRNA risk group | |||
|---|---|---|---|---|---|
| low risk, n = 12 | intermediate risk, n = 37 | high risk, n = 59 | P value | ||
| Age, year, median, (IQR) | 59 (52–68) | 51 (40–61) | 60 (52–67) | 59 (52–69) | 0.144 |
| Sex, no (%) | 0.588 | ||||
| Male | 88 (81.5%) | 11 (91.7%) | 29 (78.4%) | 48 (81.4%) | |
| Female | 20 (18.5%) | 1 (8.3%) | 8 (21.6%) | 11 (18.6%) | |
| Nuclear grade, no (%) | 0.587 | ||||
| G1 + G2 | 93 (86.1%) | 11 (91.7%) | 33 (90.2%) | 49 (83.1%) | |
| G3 + G4 | 15 (13.9%) | 1 (8.3%) | 4 (10.8%) | 10 (16.9%) | |
| Pathological T stage, no (%) | 0.039 | ||||
| pT1 + pT2 | 94 (87.0%) | 12 (100.0%) | 35 (94.6%) | 47 (80.0%) | |
| pT3 + pT4 | 14 (13.0%) | 0 (0.0%) | 2 (5.4%) | 12 (20.0%) | |
| Tumour size, mm, median (IQR) | 40 (28–50) | 30 (18–43) | 33 (28–48) | 45 (30–59) | 0.042 |
| Venous Invasion | 0.431 | ||||
| Positive | 83 (76.9%) | 11 (91.7%) | 28 (75.7%) | 44 (74.6%) | |
| Negative | 25 (23.1%) | 1 (8.3%) | 9 (24.3%) | 15 (25.4%) | |